Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]

Neil Martin; Alberto Papi; Daniel J. Bratton; Robert Chan; Peter H. Howarth; Carl B. Abbott; Oliver N. Keene; Elisabeth H. Bel

doi:10.1016/j.rmed.2020.106065

Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]

Neil Martin^*, Alberto Papi, Daniel J. Bratton, Robert Chan, Peter H. Howarth, Carl B. Abbott, Oliver N. Keene, Elisabeth H. Bel

^*Corresponding author for this work

Pulmonary medicine

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Article number	106065
Journal	Respiratory Medicine
Volume	191
DOIs	https://doi.org/10.1016/j.rmed.2020.106065
Publication status	Published - 1 Jan 2022

Access to Document

10.1016/j.rmed.2020.106065

Cite this

@article{a89a2616fcdc4ccca136039483bf5cf5,

title = "Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]",

keywords = "Biologic, Persistent asthma, Treatment",

author = "Neil Martin and Alberto Papi and Bratton, {Daniel J.} and Robert Chan and Howarth, {Peter H.} and Abbott, {Carl B.} and Keene, {Oliver N.} and Bel, {Elisabeth H.}",

note = "Funding Information: The letter was written by the authors but editorial support (in the form of minor editing and figure redrawing and referencing) was provided by Elizabeth Hutchinson PhD CMPP, at Fishawack Indicia Ltd, UK, and was funded by GSK . Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AP has received grants, personal fees, non-financial support, and other support from Chiesi Farmaceutici, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Teva, personal fees, non-financial support, and other support from Mundipharma, personal fees and non-financial support from Menarini, Novartis, and Zambon, and grants from Sanofi and Edmond Pharma. EHB has received grants for research from GSK, AstraZeneca, Teva and Novartis, and personal fees from AstraZeneca, GSK, Novartis, Teva, Sanofi/Regeneron, Sterna, Vectura, and Chiesi. NM, DB, RC, PH, CA and OK are employees of GSK and own stocks/shares.The letter was written by the authors but editorial support (in the form of minor editing and figure redrawing and referencing) was provided by Elizabeth Hutchinson PhD CMPP, at Fishawack Indicia Ltd, UK, and was funded by GSK.",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/j.rmed.2020.106065",

language = "English",

volume = "191",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Comment on

T2 - Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]

AU - Martin, Neil

AU - Papi, Alberto

AU - Bratton, Daniel J.

AU - Chan, Robert

AU - Howarth, Peter H.

AU - Abbott, Carl B.

AU - Keene, Oliver N.

AU - Bel, Elisabeth H.

N1 - Funding Information: The letter was written by the authors but editorial support (in the form of minor editing and figure redrawing and referencing) was provided by Elizabeth Hutchinson PhD CMPP, at Fishawack Indicia Ltd, UK, and was funded by GSK . Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AP has received grants, personal fees, non-financial support, and other support from Chiesi Farmaceutici, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Teva, personal fees, non-financial support, and other support from Mundipharma, personal fees and non-financial support from Menarini, Novartis, and Zambon, and grants from Sanofi and Edmond Pharma. EHB has received grants for research from GSK, AstraZeneca, Teva and Novartis, and personal fees from AstraZeneca, GSK, Novartis, Teva, Sanofi/Regeneron, Sterna, Vectura, and Chiesi. NM, DB, RC, PH, CA and OK are employees of GSK and own stocks/shares.The letter was written by the authors but editorial support (in the form of minor editing and figure redrawing and referencing) was provided by Elizabeth Hutchinson PhD CMPP, at Fishawack Indicia Ltd, UK, and was funded by GSK.

PY - 2022/1/1

Y1 - 2022/1/1

KW - Biologic

KW - Persistent asthma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85123422338&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2020.106065

DO - 10.1016/j.rmed.2020.106065

M3 - Letter

C2 - 35090690

SN - 0954-6111

VL - 191

JO - Respiratory Medicine

JF - Respiratory Medicine

M1 - 106065

ER -

Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]

Access to Document

Other files and links

Cite this